TransMedics Group, Inc. (NASDAQ:TMDX) CFO Stephen Gordon Sells 15,000 Shares

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) CFO Stephen Gordon sold 15,000 shares of TransMedics Group stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $74.01, for a total value of $1,110,150.00. Following the transaction, the chief financial officer now owns 23,299 shares of the company's stock, valued at approximately $1,724,358.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Stephen Gordon also recently made the following trade(s):

• On Friday, March 8th, Stephen Gordon sold 1,903 shares of TransMedics Group stock. The stock was sold at an average price of $87.63, for a total transaction of $166,759.89.
• On Monday, March 4th, Stephen Gordon sold 15,000 shares of TransMedics Group stock. The shares were sold at an average price of $82.80, for a total value of $1,242,000.00.
• On Thursday, February 1st, Stephen Gordon sold 15,000 shares of TransMedics Group stock. The stock was sold at an average price of $85.45, for a total value of $1,281,750.00.

TransMedics Group Trading Down 1.1 %

NASDAQ:TMDX traded down $0.81 during midday trading on Tuesday, reaching $72.62. 551,368 shares of the stock traded hands, compared to its average volume of 632,114. The stock has a market capitalization of $2.37 billion, a P/E ratio of -94.31 and a beta of 1.99. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. The company has a fifty day moving average of $82.61 and a 200 day moving average of $70.50. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $99.63.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.22. The firm had revenue of $81.20 million for the quarter, compared to analysts' expectations of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The company's revenue for the quarter was up 158.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.21) earnings per share. On average, research analysts predict that TransMedics Group, Inc. will post -0.22 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Comerica Bank purchased a new stake in shares of TransMedics Group in the 3rd quarter worth about $34,000. Global Retirement Partners LLC purchased a new stake in TransMedics Group in the third quarter worth about $38,000. Cutler Group LLC CA boosted its position in TransMedics Group by 600.0% during the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company's stock valued at $38,000 after acquiring an additional 600 shares in the last quarter. Ancora Advisors LLC bought a new stake in TransMedics Group during the 1st quarter valued at approximately $38,000. Finally, First Horizon Advisors Inc. grew its holdings in shares of TransMedics Group by 45.1% during the 1st quarter. First Horizon Advisors Inc. now owns 544 shares of the company's stock worth $41,000 after acquiring an additional 169 shares during the period. Institutional investors own 99.67% of the company's stock.

Analysts Set New Price Targets

TMDX has been the topic of a number of research reports. JPMorgan Chase & Co. upped their target price on TransMedics Group from $87.00 to $105.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 27th. Piper Sandler initiated coverage on TransMedics Group in a report on Thursday, March 28th. They set an "overweight" rating and a $95.00 target price for the company. Oppenheimer raised their price target on TransMedics Group from $92.00 to $105.00 and gave the company an "outperform" rating in a report on Tuesday, February 27th. Finally, Morgan Stanley boosted their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 28th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, TransMedics Group presently has an average rating of "Moderate Buy" and a consensus target price of $102.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.